[Clinical analysis of 19 cases of subcutaneous panniculitis T-cell lymphoma with literature review].
OBJECTIVE
Subcutaneous panniculitis T-cell lymphoma (SPTCL) is a rare subtype of primary cutaneous lymphoma. This study was to analyze the clinical characteristics, treatment and prognosis of SPTCL.


METHODS
Clinical data of 19 SPTCL patients, treated at Cancer Center and the First Affiliated Hospital of Sun Yat-sen University from January 2001 to July 2007, were analyzed.


RESULTS
The median age of the patients was 36 years. Seven patients had skin-excluded extra-nodal involvement; ten had lactate dehydragenase (LDH) elevation before treatment; one had hemophagocytic syndrome. Most of the parents received chemotherapy, including CHOP regimen, modified-alternative triple therapy (m-ATT), and Hyper-CVAD/HD-MA regimen. The median follow-up was 56 months. The median survival was 40 months, and the 2-year expected overall survival rate was 56%. Eight patients who received treatment of intensive chemotherapy had continous remission of 17-70 months; six of them underwent radiotherapy after chemotherapy. Univariate analysis (log-rank test) showed that sex, B symptoms, skin-excluded extra-nodal involvement, and pre-treatment blood cell count and LDH level affected the prognosis.


CONCLUSIONS
SPTCL might be cured by high dose chemotherapy combined with whole body irradiation. The regimens which are effective without crossing resistance or more intensive may improve the response rate and overall survival.
Huang
Jia-Jia
JJ
State Key Laboratory of Oncology in South China, Guangzhou, Guangdong 510060, P. R. China.
Cai
Mu-Yan
MY
Ye
Sheng
S
Li
Zhi-Ming
ZM
Huang
Hui-Qiang
HQ
Lin
Tong-Yu
TY
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D016410:Lymphoma, T-Cell, Cutaneous / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D015434:Panniculitis / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000532:radiotherapy; D011241:Prednisone / Q000627:therapeutic use; D012074:Remission Induction; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000532:radiotherapy; D040521:Subcutaneous Tissue; D015996:Survival Rate; D014750:Vincristine / Q000627:therapeutic use; D014916:Whole-Body Irradiation; D055815:Young Adult
D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D007770:L-Lactate Dehydrogenase; D011241:Prednisone